SG11202000086PA - Mpo inhibitors for use in medicine - Google Patents

Mpo inhibitors for use in medicine

Info

Publication number
SG11202000086PA
SG11202000086PA SG11202000086PA SG11202000086PA SG11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA
Authority
SG
Singapore
Prior art keywords
international
cambridge
pct
oaa
july
Prior art date
Application number
SG11202000086PA
Inventor
Andrew Whittaker
Hitesh Sanganee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202000086PA publication Critical patent/SG11202000086PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

FigureAverage MDA staining by flow cytometric analysis MDA staining total andrology N=29 P<0.01 r (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo nonnit Env Hs (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/016074 Al (43) International Publication Date 24 January 2019 (24.01.2019) WIP0 I PCT (51) International Patent Classification: A61K 31/505 (2006.01) A61P 15/10 (2006.01) (21) International Application Number: PCT/EP2018/068992 (22) International Filing Date: 12 July 2018 (12.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/533,448 17 July 2017 (17.07.2017) US (71) Applicant: ASTRAZENECA AB [SE/SE]; 151 85 Sodertalje (SE). (72) Inventors: WHITTAKER, Andrew; 1 Francis Crick Av- enue, Cambridge Biomedical Campus, Cambridge Cam- bridgeshire CB2 OAA (GB). SANGANEE, Hitesh, Jayan- tilal; 1 Francis Crick Avenue, Cambridge Biomedical Cam- pus, Cambridge Cambridgeshire CB2 OAA (GB). 1-1 N 1-1 C (74) Agent: LEESE, Mathew, Paul; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (54) Title: MPO INHIBITORS FOR USE IN MEDICINE Pdg Sp'? rm a Sit= N euro b SO' ,10 +Ai) C SpErm 4r4.1 1-1 (57) : The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same. C [Continued on next page] WO 2019/016074 Al IMIOHOMMIDERIDIEDIUMMIEDIRMIEMMOVOIMIE Published: — with international search report (Art. 21(3))
SG11202000086PA 2017-07-17 2018-07-12 Mpo inhibitors for use in medicine SG11202000086PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533448P 2017-07-17 2017-07-17
PCT/EP2018/068992 WO2019016074A1 (en) 2017-07-17 2018-07-12 Mpo inhibitors for use in medicine

Publications (1)

Publication Number Publication Date
SG11202000086PA true SG11202000086PA (en) 2020-02-27

Family

ID=62904484

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000086PA SG11202000086PA (en) 2017-07-17 2018-07-12 Mpo inhibitors for use in medicine

Country Status (15)

Country Link
US (2) US11246870B2 (en)
EP (1) EP3654983B1 (en)
JP (1) JP7220193B2 (en)
KR (1) KR20200029513A (en)
CN (1) CN110891572B (en)
AU (1) AU2018304508B2 (en)
BR (1) BR112019026270A2 (en)
CA (1) CA3068910A1 (en)
EA (1) EA202090266A1 (en)
ES (1) ES2963315T3 (en)
IL (1) IL272043B (en)
MA (1) MA49618A (en)
SG (1) SG11202000086PA (en)
WO (1) WO2019016074A1 (en)
ZA (1) ZA202000904B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200029513A (en) 2017-07-17 2020-03-18 아스트라제네카 아베 MPO inhibitors for use in medicine
AU2020363903A1 (en) * 2019-10-10 2022-03-24 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
CN115403584B (en) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
SE0201193D0 (en) * 2002-04-19 2002-04-19 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EA200800260A1 (en) 2005-07-05 2008-06-30 ЭДИЛЕЙД ФЭТИЛИТИ СЭНТЭ ПиТиУай ЭлТиДи The methods, compositions and combination products for the improvement of reproductive health in males or improve the outcome of pregnancy in a female, sperm (Options), process for its preparation and animal organisms that do not belong to the human race, will appear in the result of fertilization of sperm SHOWN
AR066936A1 (en) 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
JP5757604B2 (en) * 2010-02-05 2015-07-29 ヒガシマル醤油株式会社 Myeloperoxidase inhibitor
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
US11241406B2 (en) 2015-08-28 2022-02-08 Nature's Sunshine Products, Inc. Compositions and methods for acutley raising nitric oxide levels
KR20200029513A (en) 2017-07-17 2020-03-18 아스트라제네카 아베 MPO inhibitors for use in medicine

Also Published As

Publication number Publication date
AU2018304508B2 (en) 2021-06-10
US20220160715A1 (en) 2022-05-26
AU2018304508A1 (en) 2020-02-27
NZ761505A (en) 2023-09-29
BR112019026270A2 (en) 2020-06-30
EA202090266A1 (en) 2020-06-05
US20200206226A1 (en) 2020-07-02
EP3654983B1 (en) 2023-08-30
JP2020527137A (en) 2020-09-03
EP3654983A1 (en) 2020-05-27
ES2963315T3 (en) 2024-03-26
CN110891572B (en) 2023-08-15
IL272043B (en) 2022-09-01
WO2019016074A1 (en) 2019-01-24
MA49618A (en) 2020-05-27
ZA202000904B (en) 2023-04-26
CA3068910A1 (en) 2019-01-24
US11246870B2 (en) 2022-02-15
IL272043A (en) 2020-03-31
KR20200029513A (en) 2020-03-18
US11738027B2 (en) 2023-08-29
CN110891572A (en) 2020-03-17
JP7220193B2 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201811432WA (en) Rna for cancer therapy
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201909041SA (en) Anti-pd-l1 antibody and use thereof
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer